공고 • Jun 15
Moberg Pharma Reports Progress On Commercial Launch Preparations For MOB-015 (Terclara) Moberg Pharma AB (publ) announced that the first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare AB's brand. The approvals provide a defined timeline for launch preparations and marketing activities, with first deliveries planned around year-end. Launch preparations are also progressing in Israel, where the first patients are expected to gain access to the product during the third quarter of this year. Moberg Pharma's partner, Padagis, obtained marketing approval from the Israeli Ministry of Health in December 2025 and has since carried out pre-launch activities, including presentation of MOB-015 at the 3rd International Conference on Nail Disorders in Tel Aviv. Israel will be the first market where the drug MOB-015 (Terclara) is launched outside the Nordic region. As in the Nordics, the product is being launched under Moberg Pharma's brand Terclara in Israel. The first commercial deliveries are planned for the third quarter. Within the framework of the collaboration with Karo Healthcare, local approvals of updated product information and packaging materials are now ongoing. Following these approvals, commercial production can commence while launch activities are intensified, including sell-in efforts with pharmacy chains and pharmaceutical wholesalers. Karo Healthcare is leveraging its established antifungal franchise, including the Lamisil brand, and its broad European commercial platform with established distribution in all major pharmacy chains to support the rollout of MOB-015 across the region. Launch timing will subsequently depend primarily on local lead times, pharmacy chain launch windows and other market-specific conditions. The first commercial deliveries are planned around year-end, enabling start of consumer marketing activities ahead of the high season. As previously communicated, as a result of local regulatory conditions, the Lamisil brand will not be available in all markets covered by the collaboration between Moberg Pharma and Karo Healthcare, however the product will be launched using a similar visual identity and recognition factor in markets where other brands are used. In addition to Lamisil, Pevaryl, an antifungal brand within Karo Healthcare's portfolio with a strong local market position, will also be used. The companies' assessment is that the regulatory process for the approval of drug names is generally more complex in several Western European countries than in the other countries covered by the collaboration. Karo Healthcare and Moberg Pharma collaborate across 19 European markets as well as Australia, New Zealand, South Korea, Taiwan and China. The companies expect that the Lamisil brand will be used across the majority of these markets. Nail fungus is a common infection affecting approximately 10% of the general population, with the majority of patients currently untreated. The global market potential is significant, with more than hundred million patients worldwide and a clear demand for improved products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015/Terclara to be in the range of USD 250 million to USD 500 million. MOB-015/Terclara, developed by Moberg Pharma, represents the next generation of terbinafine treatment--a novel topical formulation. Oral treatments for nail fungus are associated with risks such as drug interactions and liver damage, which are avoided with topical treatment. Previous attempts at topical terbinafine treatment have failed due to the difficulty of delivering sufficient amounts of active substance through the nail. MOB-015 is the first topical treatment to achieve mycological cure rates comparable to oral therapy; mycological cure (fungal eradication) was achieved in 76% of patients in pivotal studies, and the product has received market approval in 14 countries. 공고 • May 23
Moberg Pharma AB (Publ) Approves the Election of Board Members On May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders. 공고 • Apr 18
Moberg Pharma AB (Publ) Announces Board Members Not Standing for Re-Elections Moberg Pharma AB (publ) announced that Jonas Ekblom, Otto Skolling and Nikolaj Sørensen have informed the nomination committee that they are not available for re-election at its Annual General Meeting to be held on May 21, 2026. 공고 • Mar 13
Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015 Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient. 공고 • Oct 31
Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026 Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026. 
